Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.

Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient tumor cell transduction and development of peritoneal adhesions. We have shown previously that normal virus tropism can be ablated by physically shielding the virus surface with reactive hydrophilic...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Morrison, J, Briggs, S, Green, N, Fisher, K, Subr, V, Ulbrich, K, Kehoe, S, Seymour, L
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2008

Míreanna comhchosúla

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
de réir: Morrison, J, et al.
Foilsithe / Cruthaithe: (2009)

Retargeting adenovirus gene therapy via the epidermal growth factor receptor
de réir: Morrison, J, et al.
Foilsithe / Cruthaithe: (2006)

Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
de réir: Green, N, et al.
Foilsithe / Cruthaithe: (2008)

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
de réir: Fisher, K, et al.
Foilsithe / Cruthaithe: (2001)

E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.
de réir: Bachtarzi, H, et al.
Foilsithe / Cruthaithe: (2011)

Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.
de réir: Green, N, et al.
Foilsithe / Cruthaithe: (2012)

Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.
de réir: Fisher, K, et al.
Foilsithe / Cruthaithe: (2007)

Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2008)

Improving intraperitoneal adenovirus virotherapy for ovarian cancer
de réir: Thoma, CMM
Foilsithe / Cruthaithe: (2011)

Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound.
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2013)

Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin
de réir: Dash, P, et al.
Foilsithe / Cruthaithe: (2000)

Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
de réir: Subr, V, et al.
Foilsithe / Cruthaithe: (2009)

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2009)

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2009)

Optimally stealthed Adenovirus serotype 5 shows enhanced activity and resistance to neutralisation
de réir: Thoma, C, et al.
Foilsithe / Cruthaithe: (2011)

The effect of polymer coating and different adenovirus serotypes on the innate immune responses to intraperitoneal adenovirus
de réir: Thoma, C, et al.
Foilsithe / Cruthaithe: (2008)

Adenovirus type 5 (Ad5) is sequestered and inactivated by binding to coxsackievirus and adenovirus receptor (CAR) and complement receptor 1 (CR1) on human erythrocytes
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2008)

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
de réir: Bazan-Peregrino, M, et al.
Foilsithe / Cruthaithe: (2008)

HPMA copolymers for masking and retargeting of therapeutic viruses.
de réir: Fisher, K, et al.
Foilsithe / Cruthaithe: (2010)

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.
de réir: Bachtarzi, H, et al.
Foilsithe / Cruthaithe: (2011)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
de réir: Hill, C, et al.
Foilsithe / Cruthaithe: (2021)

Virotherapy - Cancer targeted pharmacology
de réir: Tedcastle, A, et al.
Foilsithe / Cruthaithe: (2012)

Virotherapy--cancer targeted pharmacology.
de réir: Tedcastle, A, et al.
Foilsithe / Cruthaithe: (2012)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
de réir: Claudia Hill, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2006)

Glycoviruses: chemical glycosylation retargets adenoviral gene transfer.
de réir: Pearce, O, et al.
Foilsithe / Cruthaithe: (2005)

Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents
de réir: Rebeca González-Pastor, et al.
Foilsithe / Cruthaithe: (2019-02-01)

Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
de réir: Tien V Nguyen, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Novel Infectivity-Enhanced Oncolytic Adenovirus with a Capsid-Incorporated Dual-Imaging Moiety for Monitoring Virotherapy in Ovarian Cancer
de réir: Kristopher J. Kimball, et al.
Foilsithe / Cruthaithe: (2009-09-01)

The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses
de réir: Sophia J. Tate, et al.
Foilsithe / Cruthaithe: (2021-11-01)

Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition
de réir: Carlisle, R, et al.
Foilsithe / Cruthaithe: (2011)

Epidermal growth factor receptor blockers for the treatment of ovarian cancer
de réir: Morrison, J, et al.
Foilsithe / Cruthaithe: (2018)

Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
de réir: Mahasa, K, et al.
Foilsithe / Cruthaithe: (2020)

Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy
de réir: Ana Gómez, et al.
Foilsithe / Cruthaithe: (2020-09-01)

A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression
de réir: Fisher, KD, et al.
Foilsithe / Cruthaithe: (2000)

Adenovirus: teaching an old dog new tricks.
de réir: Seymour, L, et al.
Foilsithe / Cruthaithe: (2011)

An in silico approach uncovering the competency of oncolytic human adenovirus 52 for targeted breast cancer virotherapy
de réir: Muhammad Naveed, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Lactoferrin Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated Pyroptotic Response in Human Phagocytes
de réir: Coraline Chéneau, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein
de réir: Elisabeth A van Erp, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Oncolytic virotherapy: combining first-rate science with an unmet clinical need.
de réir: Seymour, L
Foilsithe / Cruthaithe: (2011)